Search Results - "Croteau, S"

Pharmacokinetics and the transition to extended half‐life factor concentrates: communication from the SSC of the ISTH by Ragni, M. V., Croteau, S. E., Morfini, M., Cnossen, M. H., Iorio, A.

“…Summary Extended half‐life proteins (EHL) are increasingly used in clinical practice, but there is no standardized approach to sampling, interpretation and…”
Get full text

Transition considerations for extended half-life factor products by Croteau, S. E., Neufeld, E. J.

Get full text

The spectrum of bleeding in women and girls with haemophilia B by Staber, J., Croteau, S. E., Davis, J., Grabowski, E. F., Kouides, P., Sidonio, R. F.

“…Although hemophilia B affects 1 in 25,000 males there may be 3 female hemophilia B carriers per affected male. This clinical review highlights the unique…”
Get full text

Recombinant porcine factor VIII for high‐risk surgery in paediatric congenital haemophilia A with high‐titre inhibitor by Croteau, S. E., Abajas, Y. L., Wolberg, A. S., Nielsen, B. I., Marx, G. R., Baird, C. W., Neufeld, E. J., Monahan, P. E.

“…Introduction High‐titre factor VIII (FVIII) inhibitors complicate peri‐operative haemostasis. Recombinant porcine FVIII (r‐pFVIII) may provide an alternative…”
Get full text

Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States by Farber, Harrison W., Germack, Hayley D., Croteau, Nicole S., Simeone, Jason C., Tang, Fei, Paoli, Carly J., Doad, Gurinderpal, Panjabi, Sumeet, De Marco, Teresa

“…Information on factors leading to pulmonary arterial hypertension (PAH) treatment discontinuation is limited. This study analyzed 12,902 new PAH medication…”
Get full text

Author's response: 'Transition considerations for extended half-life factor products' by Croteau, S. E., Neufeld, E. J.

Get full text

Fifth Åland Island conference on von Willebrand disease by Berntorp, E., Ågren, A., Aledort, L., Blombäck, M., Cnossen, M. H., Croteau, S. E., Depka, M., Federici, A. B., Goodeve, A., Goudemand, J., Mannucci, P. M., Mourik, M., Önundarson, P. T., Rodeghiero, F., Szántó, T., Windyga, J.

“…The fifth Åland Island meeting on von Willebrand disease (VWD) was held on the Åland Islands, Finland, from 22 to 24 September 2016—90 years after the first…”
Get full text

Correlation between dispensed and prescribed doses of factor products for bleeding disorders: can a small, centre-based pharmacy hit the mark? by Croteau, S. E., Saxena, K., Neufeld, E. J.

“…Summary The prescribing and dispensing of factor replacement products have come under scrutiny in recent years. Some payers are shunting patients away from…”
Get full text

Systolic blood pressure as a predictor of transient ischemic attack/minor stroke in emergency department patients under age 80: a prospective cohort study by Penn, Andrew M, Croteau, Nicole S, Votova, Kristine, Sedgwick, Colin, Balshaw, Robert F, Coutts, Shelagh B, Penn, Melanie, Blackwood, Kaitlin, Bibok, Maximilian B, Saly, Viera, Hegedus, Janka, Yu, Amy Y X, Zerna, Charlotte, Klourfeld, Evgenia, Lesperance, Mary L

“…Elevated blood pressure (BP) at emergency department (ED) presentation and advancing age have been associated with risk of ischemic stroke; however, the…”
Get full text

Reducing time-to-unit among patients referred to an outpatient stroke assessment unit with a novel triage process: a prospective cohort study by Bibok, Maximilian B, Votova, Kristine, Balshaw, Robert F, Lesperance, Mary L, Croteau, Nicole S, Trivedi, Anurag, Morrison, Jaclyn, Sedgwick, Colin, Penn, Andrew M

“…To evaluate the performance of a novel triage system for Transient Ischemic Attack (TIA) units built upon an existent clinical prediction rule (CPR) to reduce…”
Get full text

Treatment Outcomes of Low-grade Lymphoma of the Orbit by Holloway, C.L., Pickles, T., Croteau, N.S., Wai, E.S.

“…Radiation therapy can be used with curative intent in patients with low-grade orbital non-Hodgkin's lymphoma (NHL) stages IE and IVE (limited to the bilateral…”
Get full text

Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab by Ksienski, Doran, Wai, Elaine S., Alex, Deepu, Croteau, Nicole S., Freeman, Ashley T., Chan, Angela, Patterson, Tiffany, Clarkson, Melissa, Fiorino, Leathia, Poonja, Zia, Fenton, David, Irons, Sarah, Lesperance, Mary

Get full text

White Matter Hyperintensity Volume Influences Symptoms in Patients Presenting With Minor Neurological Deficits by Zerna, Charlotte, Yu, Amy Y.X., Hong, Zachary M., Penn, Andrew M., Lesperance, Mary L., Croteau, Nicole S., Balshaw, Robert F., Votova, Kristine, Bibok, Maximilian B., Saly, Viera, Modi, Jayesh, Hegedus, Janka, Klourfeld, Evgenia, Coutts, Shelagh B.

“…BACKGROUND AND PURPOSE—Acute minor neurological deficits are a common complaint in the emergency department and differentiation of transient ischemic…”
Get full text

Immune related adverse events and treatment discontinuation in patients older and younger than 75 years with advanced melanoma receiving nivolumab or pembrolizumab by Ksienski, Doran, Truong, Pauline T., Croteau, Nicole S., Chan, Angela, Sonke, Eric, Patterson, Tiffany, Clarkson, Melissa, Hackett, Samuel, Lesperance, Mary

“…Programmed cell-death 1 antibodies (PD-1 Ab) improve overall survival (OS) for patients with advanced melanoma in trials; however, safety data in patients…”
Get full text

Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-based Cohort by Ksienski, D., Truong, P.T., Wai, E.S., Croteau, N.S., Chan, A., Patterson, T., Clarkson, M., Hackett, S., Irons, S., Lesperance, M.

“…Induction ipilimumab and nivolumab followed by maintenance nivolumab improve overall survival compared with ipilimumab alone in patients with advanced…”
Get full text

Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab by Ksienski, Doran, Wai, Elaine S., Croteau, Nicole S., Freeman, Ashley T., Chan, Angela, Fiorino, Leathia, Poonja, Zia, Fenton, David, Patterson, Tiffany, Irons, Sarah, Lesperance, Mary

“…To explore the association of age with development of immune related adverse events (irAE) and survival in patients with advanced nonsmall cell lung cancer…”
Get full text

27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study by Saltman, David L., Varga, Matthew G., Nielsen, Tyler J., Croteau, Nicole S., Lockyer, Heather M., Jain, Amit L., Vidal, Gregory A., Hout, David R., Schweitzer, Brock L., Seitz, Robert S., Ross, Douglas T., Gandara, David R.

“…Immune checkpoint inhibitors (ICI) are standard of care in advanced non-small cell lung cancer (NSCLC). However, not all patients benefit, even among PD-L1…”
Get full text

Individualized prescribing portraits to reduce inappropriate initiation of opioid analgesics to opioid naïve patients in primary care: Protocol for a randomized controlled trial by Klimas, J., Hamilton, M.A., Carney, G., Cooper, I.R., Croteau, N.S., Dong, H., Dormuth, C., Maclure, M., Socías, M.E., Ti, L., Wood, E., McCracken, R.

“…Background Opioid analgesics are frequently initiated for chronic and acute pain despite weak evidence of benefit, although prescribing rates of some…”
Get full text

Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice by Ksienski, Doran, Truong, Pauline T, Croteau, Nicole S, Chan, Angela, Sonke, Eric, Patterson, Tiffany, Clarkson, Melissa, Lesperance, Mary

“…Background The anti-programmed cell death one antibodies (Anti-PD-1 Ab) pembrolizumab or nivolumab are commonly prescribed to patients with advanced melanoma…”
Get full text

Verification of a proteomic biomarker panel to diagnose minor stroke and transient ischaemic attack: phase 1 of SpecTRA, a large scale translational study by Penn, Andrew M., Bibok, Maximilian B., Saly, Viera K., Coutts, Shelagh B., Lesperance, Mary L., Balshaw, Robert F., Votova, Kristine, Croteau, Nicole S., Trivedi, Anurag, Jackson, Angela M., Hegedus, Janka, Klourfeld, Evgenia, Yu, Amy Y. X., Zerna, Charlotte, Borchers, Christoph H.

“…Objective: To derive a plasma biomarker protein panel from a list of 141 candidate proteins which can differentiate transient ischaemic attack (TIA)/minor…”
Get full text